Trends in Prescription Drug Launch Prices, 2008-2021

Benjamin N. Rome · Alexander C. Egilman · Aaron Seth Kesselheim

111 citations0/0 files storedJAMA

No readable copy stored yet — this record is metadata only.

No open-access location is known for this record yet.

Literature note Cite in a project Citation map

Pharmaceutical Economics and Policy Healthcare Policy and Management Pharmaceutical industry and healthcare

Abstract

This study uses SSR Health data on drug list prices and estimated net prices after manufacturer discounts to evaluate trends in prices for newly marketed brand-name prescription drugs in the US from 2008 to 2021.

Paper brief

Loading…

Cite this work

Citation unavailable for this work.

BibTeX RIS CSL-JSON

No public copy is stored for this record, so only the metadata is cited.

Citations in this library

Citation map →

Stored only when both papers are in the corpus — 111 citations exist upstream.

References

2016The High Cost of Prescription Drugs in the United States 2020Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018

Cited by

2024Population-health impact of new drugs recommended by the National Institute for Health and Care Excellence in England during 2000–20: a retrospective analysis 2023High drug prices are not justified by industry’s spending on research and development 2023The association between cost sharing, prior authorization, and specialty drug utilization: A systematic review

Explore the map →

Papers that cite the same references — the relational fallback while embeddings are still backfilling.

Imported from OpenAlex (CC0) — nothing here is generated.